Glycaemic Control after Metformin Discontinuation in Diabetic Patients with a Declining Renal Function
Table 2
Characteristics of the patients with improved glycaemia (HbA1c decreased >0.5% at 6-month follow-up from baseline) and worsened glycaemia (HbA1c increased >0.5% at 6-month follow-up from baseline) following metformin discontinuation.
Total cohort ()
Worsened glycaemia ()
Improved glycaemia ()
p value comparing worsened versus improved glycaemia
Age, years
66.7 (10.9)
68.1 (9.13)
65.0 (13.3)
0.339
Male, %
54
60
64
0.771
Diabetes duration, years
18.2 (8.3)
20.4 (7.48)
15.3 (7.4)
0.020
Medications at metformin discontinuation, %
Insulin
51
52
56
0.776
Sulfonylurea
42
40
36
0.771
DPP-IV inhibitor
7
8
8
1.000
HbA1c, %
At baseline
8.8 (2.3)
8.1 (2.0)
10.1 (2.5)
0.002
At 3 months
9.2 (2.2)
9.8 (2.6)a
9.1 (2.3)
At 6 months
9.0 (2.2)
10.4 (2.6)b
8.3 (1.7)b
Body weight, kg
At baseline
71.8 (12.9)
75.3 (14.4)
68.7 (14.4)
0.107
At 3 months
72.4 (13.0)
75.5 (13.9)
71.4 (13.6)
At 6 months
72.8 (12.2)
76.4 (13.1)
71.1 (14.0)
eGFR, ml/minute/1.73 m2
eGFR at baseline
29.7 (13.0)
29.6 (8.5)
33.0 (12.3)
0.250
eGFR at 3 months
27.5 (10.8)
30.1 (14.7)
25.9 (10.5)a
eGFR at 6 months
26.3 (11.2)
29.8 (17.2)
23.8 (9.1)b
Values are in mean (SD) unless stated otherwise. for comparison between baseline and at 3-month follow-up. for comparison between baseline and at 6-month follow-up.
